Latest Commercialization News

Centuria Capital Group reported a robust FY25 with $19.7 billion in assets under management and earnings per stapled security exceeding guidance. The group is poised for strong FY26 growth, driven by stabilizing real estate markets and its pioneering sovereign AI Factory.

Spenda Limited has locked in a $3.5 million convertible loan facility with Obsidian Global GP, LLC, aiming to strengthen its working capital and edge closer to operational break-even.

Argent BioPharma has signed a binding term sheet to acquire key assets from AusCann Group Holdings, significantly expanding its clinical pipeline, intellectual property, and European manufacturing and distribution capabilities ahead of a planned US stock exchange listing.

Wide Open Agriculture has launched a pre-feasibility study for a large-scale lupin protein facility in Western Australia, aiming to establish a new global food category and reduce production costs. This move marks a pivotal step toward commercial scale and global leadership in sustainable plant-based proteins.

Carnaby Resources has completed its acquisition of the Trekelano mining leases, advancing exploration and integration efforts within its Greater Duchess Copper Gold Project.

AnteoTech has appointed Merrill Gray as its new Managing Director and CEO following a successful interim period, while issuing over 22 million shares to staff under its FY2025 incentive program.

OD6 Metals has raised $2.5 million through a strongly supported placement to fast-track rare earth testwork and copper drilling programs at its flagship Australian projects.

Sun Silver Limited has confirmed significant high-grade silver, gold, and antimony mineralisation at surface through rock chip sampling at its Maverick Springs Project in Nevada, highlighting potential for early-stage revenue and resource expansion.

AdAlta Limited outlines its innovative 'East to West' cellular immunotherapy approach, in-licensing Asian CAR-T assets and progressing clinical trials in Australia to unlock value. The company also seeks partners for its anti-fibrotic and anti-malarial protein therapeutics.

Amplitude Energy Limited reported a 22% revenue increase to A$268.1 million for FY25, narrowing its net loss significantly while progressing its East Coast Supply Project with a new joint venture partner.

CSL Limited reported solid FY25 financials with 5% revenue growth and announced a strategic transformation including a $500 million annual cost saving target and plans to spin off its vaccine business, CSL Seqirus, as a separate ASX-listed entity.

CSL Limited reported robust FY25 results alongside a sweeping strategic overhaul, including a major cost-saving program and plans to spin off its vaccine unit CSL Seqirus as a standalone ASX-listed company.